Definium Therapeutics CEO Robert Barrow sells $721,732 in shares

Definium Therapeutics CEO Robert Barrow sold 19,023 shares of the company's common stock on September 3, 2026, for a total of $721,732. The shares were sold at prices ranging from $37.46 to $38.94, and the transaction was executed under a Rule 10b5-1 plan to satisfy withholding tax obligations related to the settlement of vested performance restricted stock units.

This sale comes after the acquisition of 40,000 shares on September 2, 2026, which were granted as performance share units contingent upon specific clinical and regulatory milestones. Following the sale, Barrow directly holds 1,494,640 shares of Definium Therapeutics, Inc. Analysts have noted that the stock appears slightly overvalued at current levels and have provided mixed recommendations, with some raising price targets and others expressing confidence in the company's future prospects.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.